Home > Cardiology > ESC 2022 > Fears regarding effect of neprilysin inhibition on cognition removed

Fears regarding effect of neprilysin inhibition on cognition removed

Presented By
Prof. John McMurray, University of Glasgow, UK
Conference
ESC 2022
Trial
Phase 3, PERSPECTIVE
Initial results of the PERSPECTIVE trial demonstrated no evidence that neprilysin inhibition increased the risk of cognitive impairment, due to accumulation of amyloid-β in the brain, in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). These data should set to rest concerns about increased cerebral amyloid-β deposition with sacubitril/valsartan related to neprilysin inhibition. Sacubitril/valsartan is the first of the class of dual neprilysin and angiotensin receptor inhibitors (ARNI). "Neprilysin is one of the many enzymes involved in the proteolytic breakdown of amyloid-β peptides, one of which (amyloid-β1–42) may be neurotoxic and is associated with Alzheimer's disease, for example, and concern was raised that their accumulation in the brain during sustained inhibition of neprilysin could cause or worsen cognitive impairment,” Prof. John McMurray (University of Glasgow, UK) explained as ra...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on